PROCEPT BioRobotics Corporation Common Stock (PRCT) is a publicly traded Healthcare sector company. As of November 5, 2026, PRCT trades at $19.49 with a market cap of $1.16B and a P/E ratio of -9.15. PRCT moved -10.00% today. Year to date, PRCT is -34.63%; over the trailing twelve months it is -38.17%. Its 52-week range spans $16.67 to $66.85. Analyst consensus is neutral with an average price target of $22.89. Rallies surfaces PRCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Procept Biorobotics Q3 revenue misses estimates; 2026 revenue outlook reiterated: Procept Biorobotics reported Q3 revenue of $98.29 million, up 18% year over year but below the $102.56 million estimate, and an adjusted EBITDA loss of $9.82 million versus an estimated $5.68 million loss. It reiterated 2026 revenue guidance of $390 million to $410 million.
| Metric | Value |
|---|---|
| Price | $19.49 |
| Market Cap | $1.16B |
| P/E Ratio | -9.15 |
| EPS | $-1.94 |
| Dividend Yield | 0.00% |
| 52-Week High | $66.85 |
| 52-Week Low | $16.67 |
| Volume | 5.52K |
| Avg Volume | 0 |
| Revenue (TTM) | $337.34M |
| Net Income | $-109.75M |
| Gross Margin | 64.22% |
12 analysts cover PRCT: 0 strong buy, 4 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $22.89.